Please login to the form below

Not currently logged in
Email:
Password:

Manish Singh resigns as CEO of ImmunoCellular Therapeutics

Replaced on interim basis by company chair and chief scientific officer Dr John Yu

John Yu - ImmunoCellularDr Manish Singh has stepped down as CEO of ImmunoCellular Therapeutics to be replaced by the company's founder Dr John Yu (pictured) on an interim basis.

US-based cancer specialist ImmunoCellular said that Dr Singh has left to "pursue other opportunities" having joined as president and CEO of the company in February 2008.

In that time, the company has focused on its lead candidate ICT-107, a cell-based vaccine in phase II development to target glioblastoma brain tumours.

The drug's progress will now be overseen by Dr Yu, who asserted his confidence in the treatment's potential, as well as ImmunoCellular's other pipeline products.

“We hope that this trial will provide clinical validation of our platform and represent a potential breakthrough treatment for this deadly and intractable cancer," he said.

“We intend to continue to make progress in advancing our earlier stage product candidates, with the recent approval of an IND to initiate a phase I trial of ICT-121 targeting CD133-positive cancer stem cells. We are developing a phase I study with ICT-140 to treat ovarian cancer.”

Dr Yu is the chief scientific officer and chair of ImmunoCellular in addition to serving on the faculty of the Department of Neurosurgery at Cedars-Sinai Medical Center.

He will continue as interim CEO while a search for a permanent replacement for Dr Singh is carried out.

22nd August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics